Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Fusion Pharmaceuticals brings in $105mm through Series B round

Executive Summary

Fusion Pharmaceuticals Inc. (radiopharmaceuticals for cancer) raised $105mm through an oversubscribed Series B round led by Varian and OrbiMed. Perceptive Advisors, Pivotal bioVenture Partners, and Rock Springs Capital were joined by returning backers HealthCap, Adams Street Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), TPG Biotech, Seroba Life Sciences, Genesys Capital, and FACIT. OrbiMed, Pivotal bioVenture, and Varian join the company's board. Fusion will use the proceeds to support continued development of its pipeline of alpha therapeutics designed with the company's Fast-Clear platform for linking molecules to medical isotopes.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies